New Lysosomal Stress Pathway Linking TBK1 and TFEB Could Reshape Cancer and Aging Biology
Scientists uncover a nutrient-independent signaling axis that activates TFEB, a master regulator of cellular cleanup, with direct implications for cancer and longevity.
Summary
Cells must constantly adapt their internal recycling machinery — lysosomes — to survive stress. A key protein called TFEB orchestrates this cleanup process and is known to influence both aging and cancer. Researchers have now discovered a previously unknown signaling pathway in which two kinases, TBK1 and ULK1, are recruited to the lysosome surface during stress and disable a molecular brake called FLCN, freeing TFEB to enter the nucleus and activate cellular recycling programs. Crucially, this pathway operates independently of nutrient status, revealing a fundamentally new way cells regulate lysosomal function. The team also found that specific mutations in the v-ATPase proton pump — seen in follicular lymphoma patients — hijack this pathway, locking TFEB in a hyperactive state that drives tumor growth. These findings open new avenues for targeting lysosomal signaling in both cancer treatment and age-related disease.
Detailed Summary
Lysosomes are the cell's primary recycling centers, breaking down damaged proteins and organelles to maintain metabolic balance. Their regulation is critical not only for basic cellular health but also for aging, neurodegeneration, and cancer. At the heart of lysosomal control sits TFEB, a transcription factor that, when active, drives the expression of genes responsible for autophagy and lysosomal biogenesis. Understanding what turns TFEB on and off has been a major research priority.
This new study, published in Nature, identifies a previously unknown signaling axis linking lysosomal stress to TFEB activation. The researchers show that when lysosomes are stressed, two kinases — TBK1 and ULK1 — are recruited to the lysosome via a protein adaptor called TAX1BP1, driven by the v-ATPase proton pump. Once at the lysosome, these kinases phosphorylate FNIP1 at serine 296, which disables the FLCN-FNIP complex. FLCN normally acts as a brake on TFEB by enabling mTORC1 to keep TFEB out of the nucleus. With FLCN inhibited, TFEB translocates to the nucleus and activates catabolic gene programs.
Critically, this pathway operates independently of nutrient availability — a key distinction from the well-known mTORC1-nutrient sensing axis. This means cells have a dedicated, nutrient-agnostic mechanism to ramp up lysosomal activity in response to stress signals alone.
The study further reveals that recurrent mutations in ATP6V1B2, a subunit of the v-ATPase pump found in follicular lymphoma patients, constitutively activate this TBK1/ULK1-TFEB pathway, effectively keeping TFEB hyperactive. This drives unchecked lysosomal and catabolic activity that supports tumor proliferation, identifying TFEB as a functional oncogene in this context.
For longevity science, these findings are significant: TFEB activation is associated with improved autophagy, proteostasis, and lifespan extension in model organisms. Discovering a druggable kinase axis that controls TFEB offers potential new targets for interventions aimed at boosting cellular cleanup in aging tissues — and for suppressing its excess in cancer.
Key Findings
- TBK1 and ULK1 kinases are recruited to lysosomes during stress via TAX1BP1, activating TFEB independently of nutrient signals.
- Phosphorylation of FNIP1 at S296 by TBK1/ULK1 disables the FLCN brake, freeing TFEB to enter the nucleus.
- v-ATPase mutations found in follicular lymphoma constitutively activate this pathway, driving TFEB hyperactivation and tumor growth.
- TFEB is confirmed as a functional oncogene in follicular lymphoma via this novel lysosomal stress mechanism.
- The pathway is nutrient-independent, revealing a new layer of lysosomal regulation with implications for aging and disease.
Methodology
The study combined biochemical signaling assays, phosphoproteomic analysis, and cancer patient mutation data to map the TBK1/ULK1-FNIP1-FLCN-TFEB axis. Researchers validated findings in follicular lymphoma patient samples carrying ATP6V1B2 v-ATPase mutations. Full methodology details are not available as this summary is based on the abstract only.
Study Limitations
This summary is based on the abstract only; full experimental details, model systems used, and the breadth of validation are unavailable. The direct translational relevance to human aging (as opposed to cancer) remains to be established in dedicated aging models. Competing interest disclosures note co-founders of Casma Therapeutics among the senior authors, which warrants consideration when evaluating conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: